Josip A Borovac1, Zoran Dogas2,3, Daniela Supe-Domic4, Tea Galic2,5, Josko Bozic6,7. 1. Department of Pathophysiology, University of Split School of Medicine, Soltanska 2, 21000, Split, Croatia. 2. Department of Neuroscience, University of Split School of Medicine, Soltanska 2, 21000, Split, Croatia. 3. Sleep Medicine Center, University of Split School of Medicine, Soltanska 2, 21000 Split and University Hospital of Split, Spinciceva 1, 21000, Split, Croatia. 4. Department of Medical Laboratory Diagnostics, University Hospital of Split, Spinciceva 1, 21000, Split, Croatia. 5. Study of Dental Medicine, University of Split School of Medicine, Soltanska 2, 21000, Split, Croatia. 6. Department of Pathophysiology, University of Split School of Medicine, Soltanska 2, 21000, Split, Croatia. josko.bozic@mefst.hr. 7. Department of Neuroscience, University of Split School of Medicine, Soltanska 2, 21000, Split, Croatia. josko.bozic@mefst.hr.
Abstract
PURPOSE: Obstructive sleep apnea (OSA) is a complex sleep disorder associated with autonomic and sympathetic dysregulation. To the contrary, catestatin, an endogenous pleiotropic peptide cleaved from chromogranin A, is known for its inhibitory effects on catecholamine release and sympathetic activity. The aims of the study were to determine catestatin serum levels among male OSA patients compared to healthy control subjects and to explore associations of catestatin with anthropometric, polysomnographic, and lipid profile parameters. METHODS: Seventy-eight male OSA patients aged 50.3 ± 8.8 years and 51 age/sex/BMI-matched control subjects aged 50.4 ± 7.8 years were enrolled in the study. Catestatin serum levels were determined by an enzyme-linked immunosorbent assay (ELISA). RESULTS: Catestatin serum levels were significantly higher among OSA patients compared to control subjects (2.9 ± 1.2 vs. 1.5 ± 1.1 ng/mL, p < 0.001). Serum catestatin levels significantly correlated with apnea-hypopnea index (AHI) among non-obese OSA subjects (r = 0.466, p = 0.016; β = 0.448, p = 0.026), while in whole OSA population, catestatin levels significantly correlated with neck circumference (r = 0.318, p < 0.001; β = 0.384, p < 0.001) and high-density lipoprotein (HDL) cholesterol (r = - 0.320, p < 0.001; β = - 0.344, p < 0.001). In multivariate-adjusted regression model, serum catestatin was significant and independent predictor of OSA status (OR 4.98, 95% CI 2.17-11.47, p < 0.001). CONCLUSIONS: Catestatin serum levels are significantly increased in male OSA population and positively correlate with disease severity in non-obese patients. OSA status is independently predicted by catestatin levels; however, this finding is restricted to patients with moderate-to-severe disease. Further studies are necessary to elucidate the mechanistic role of catestatin in the complex pathophysiology of OSA.
PURPOSE:Obstructive sleep apnea (OSA) is a complex sleep disorder associated with autonomic and sympathetic dysregulation. To the contrary, catestatin, an endogenous pleiotropic peptide cleaved from chromogranin A, is known for its inhibitory effects on catecholamine release and sympathetic activity. The aims of the study were to determine catestatin serum levels among male OSA patients compared to healthy control subjects and to explore associations of catestatin with anthropometric, polysomnographic, and lipid profile parameters. METHODS: Seventy-eight male OSA patients aged 50.3 ± 8.8 years and 51 age/sex/BMI-matched control subjects aged 50.4 ± 7.8 years were enrolled in the study. Catestatin serum levels were determined by an enzyme-linked immunosorbent assay (ELISA). RESULTS:Catestatin serum levels were significantly higher among OSA patients compared to control subjects (2.9 ± 1.2 vs. 1.5 ± 1.1 ng/mL, p < 0.001). Serum catestatin levels significantly correlated with apnea-hypopnea index (AHI) among non-obese OSA subjects (r = 0.466, p = 0.016; β = 0.448, p = 0.026), while in whole OSA population, catestatin levels significantly correlated with neck circumference (r = 0.318, p < 0.001; β = 0.384, p < 0.001) and high-density lipoprotein (HDL) cholesterol (r = - 0.320, p < 0.001; β = - 0.344, p < 0.001). In multivariate-adjusted regression model, serum catestatin was significant and independent predictor of OSA status (OR 4.98, 95% CI 2.17-11.47, p < 0.001). CONCLUSIONS:Catestatin serum levels are significantly increased in male OSA population and positively correlate with disease severity in non-obesepatients. OSA status is independently predicted by catestatin levels; however, this finding is restricted to patients with moderate-to-severe disease. Further studies are necessary to elucidate the mechanistic role of catestatin in the complex pathophysiology of OSA.
Authors: Virend K Somers; David P White; Raouf Amin; William T Abraham; Fernando Costa; Antonio Culebras; Stephen Daniels; John S Floras; Carl E Hunt; Lyle J Olson; Thomas G Pickering; Richard Russell; Mary Woo; Terry Young Journal: Circulation Date: 2008-08-25 Impact factor: 29.690
Authors: Kathryn C B Tan; Wing-Sun Chow; Jamie C M Lam; Bing Lam; Wai-Keung Wong; Sidney Tam; Mary S M Ip Journal: Atherosclerosis Date: 2005-06-21 Impact factor: 5.162
Authors: Jianguo Li; Laura N Thorne; Naresh M Punjabi; Cheuk-Kwan Sun; Alan R Schwartz; Philip L Smith; Rafael L Marino; Annabelle Rodriguez; Walter C Hubbard; Christopher P O'Donnell; Vsevolod Y Polotsky Journal: Circ Res Date: 2005-08-25 Impact factor: 17.367
Authors: Jianguo Li; Dmitry N Grigoryev; Shui Qing Ye; Laura Thorne; Alan R Schwartz; Philip L Smith; Christopher P O'Donnell; Vsevolod Y Polotsky Journal: J Appl Physiol (1985) Date: 2005-07-21
Authors: Lawrence J Epstein; David Kristo; Patrick J Strollo; Norman Friedman; Atul Malhotra; Susheel P Patil; Kannan Ramar; Robert Rogers; Richard J Schwab; Edward M Weaver; Michael D Weinstein Journal: J Clin Sleep Med Date: 2009-06-15 Impact factor: 4.062
Authors: Daniel T O'Connor; Mala T Kailasam; Brian P Kennedy; Michael G Ziegler; Noboru Yanaihara; Robert J Parmer Journal: J Hypertens Date: 2002-07 Impact factor: 4.844
Authors: Toni Kljakovic-Gaspic; Daria Tokic; Dinko Martinovic; Marko Kumric; Daniela Supe-Domic; Sanda Stojanovic Stipic; Nikola Delic; Josip Vrdoljak; Marino Vilovic; Tina Ticinovic Kurir; Josko Bozic Journal: J Clin Med Date: 2022-08-02 Impact factor: 4.964